Dose: 50 to 165 mg/m2
Single Dose: 110 (107.5)
Frequency: 24 hourly
Route: IV
Instructions: Initially for 5 days then twice weekly as a 30-60 minutes infusion solution of upto 1mg/ml in NaCl 0.9% or D5W.

Teniposide also known as EPT. . It is of Semi Synthetic origin and belongs to Podophyllotoxins. . The Molecular Weight of Teniposide is 656.70.

Teniposide is contraindicated in conditions like Hypersensitivity to the drug.

The severe or irreversible adverse effects of Teniposide, which give rise to further complications include Bone marrow depression, Bleeding.The symptomatic adverse reactions produced by Teniposide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Nausea and vomiting, Swelling, Hypersensitivity reactions.

Teniposide is primarily indicated in conditions like Acute lymphocytic leukemia, and can also be given in adjunctive therapy as an alternative drug of choice in Glioblastoma, Neuroblastoma, Retinoblastoma.

Teniposide is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCyclosporin ACiclosporin decreases the clearance of teniposide, with increase terminal half-life, peak plasma concentration and toxicity.MethotrexateConcurrent use may increase the plasma clearance of methotrexate.Phenytoin (Na)Phenytoin and phenobarbital increases the clearance of teniposide, the resultant decrease in systemic exposure might reduce its efficacy.The dose of teniposide need to be reduced.Sodium SalicylateConcurrent use may result in potentiation of drug toxicity.SulphamethizoleConcurrent use may result in potentiation of drug toxicity.TolbutamideConcurrent use may result in potentiation of drug toxicity.VORICONAZOLEVoriconazole, may decrease the metabolism and clearance of Teniposide Consider alternate therapy or monitor carefully These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Teneposide is a potent drug and should be used only by physicians experienced in the administration of cancer chemotherapeutic drugs. Blood counts as well as renal and hepatic function tests should be carefully monitored prior to and during therapy. Physicians should be aware of the possible occurrence of a hypersensitivity reaction variably manifested by chills, fever, urticaria, tachycardia, bronchospasm, dyspnea, hypertension or hypotension and facial flushing. This reaction may occur with the first dose of teneposide and may be life threatening if not treated promptly with antihistamines, corticosteroids, epinephrine, intravenous fluids and other supportive measures as clinically indicated. In all instances where the use of Teneposide is considered for chemotherapy, the physician must evaluate the need and usefulness of the drug against the risk of adverse reactions. Most such adverse reactions are reversible if detected early. If severe reactions occur, the drug should be reduced in dosage or discontinued and appropriate corrective measures should be taken according to the clinical judgment of the physician. Reinstitution of Teneposide therapy should be carried out with caution, and with adequate consideration of the further need for the drug and alertness as to possible recurrence of toxicity.